In the field of orofacial surgery, a red blood cell transfusion (RBCT) is occasionally required during double jaw and oral cancer surgery. However, the question remains whether the effect of RBCT during the perioperative period is beneficial or harmful. The answer to this question remains challenging. In the field of orofacial surgery, transfusion is performed for the purpose of oxygen transfer to hypoxic tissues and plasma volume expansion when there is bleeding. However, there are various risks, such as infectious complications (viral and bacterial), transfusion-related acute lung injury, ABO and non-ABO associated hemolytic transfusion reactions, febrile non-hemolytic transfusion reactions, transfusion associated graft-versus-host disease, transfusion associated circulatory overload, and hypersensitivity transfusion reaction including anaphylaxis and transfusion-related immune-modulation. Many studies and guidelines have suggested RBCT is considered when hemoglobin levels recorded are 7 g/dL for general patients and 8-9 g/dL for patients with cardiovascular disease or hemodynamically unstable patients. However, RBCT is occasionally an essential treatment during surgeries and it is often required in emergency cases. We need to comprehensively consider postoperative bleeding, different clinical situations, the level of intra-and postoperative patient monitoring, and various problems that may arise from a transfusion, in the perspective of patient safety. Since orofacial surgery has an especially high risk of bleeding due to the complex structures involved and the extensive vascular distribution, measures to prevent bleeding should be taken and the conditions for a transfusion should be optimized and appropriate in order to promote patient safety.
INTRODUCTION
In the field of orofacial surgery, a red blood cell transfusion (RBCT) is often needed during either double jaw or oral cancer surgery. RBCT can be a life-saving procedure for most patients with acute anemia caused by perioperative bleeding; on the contrary, it also presents various risks, such as infectious complications (viral and bacterial), transfusion-related acute lung injury, ABO and non-ABO associated hemolytic transfusion reactions, febrile non-hemolytic transfusion reactions, transfusion associated graft-versus-host disease, transfusion-associated circulatory overload, and hypersensitivity transfusion reactions, including anaphylaxis, and transfusion-related immune-modulation (TRIM) [1, 2] . In the field of transfusion medicine, three studies have used propensity score matching with regard to transfusion and mortality namely, the ABC [3] , CRIT [4] , and SOAP [5] studies. The ABC and CRIT studies considered RBCT as an independent
PHYSIOLOGICAL PRINCIPLES
Oxygen transfer to the tissues in the human body involves RBCs that carry hemoglobin-bound oxygen from the lungs to the cells. Under resting conditions, the amount of oxygen supplied exceeds the oxygen demand of the tissues. This margin of safety for oxygen transport is needed for emergency situations, such as bleeding, when oxygen demand spikes rapidly; however, if excessive bleeding exceeds this safety margin, transfusion becomes necessary in order to supply enough oxygen to the peripheral vascular system and the tissues.
RBCT increases the ability to deliver oxygen to hypoxic tissues under acute anemia conditions (perioperative bleeding), as well as with diseases such as sickle cell disease or malaria. It is also responsible for carrying out a hemostatic role by increasing coagulation [10] , and recent findings have indicated its involvement in clot contractions [11] . Moreover, it is also performed for the purpose of plasma volume expansion in cases of possible clinically significant perioperative bleeding.
TRANSFUSION STRATEGY & TRIGGER
The indications and triggers for RBCT are on-going issues. There have been many studies and there are still on-going studies in search of an answer. Based on studies to date, there are two strategies. Historically, the threshold that triggered a RBCT has been based on a liberal strategy (hemoglobin [Hb] level below 10 g/dL or hematocrit
[Hct] below 30%). In 1988, the "10/30 Rule" was presented at the National Institutes of Health Consensus Development Conference, which presented the level of RBCT during perioperative period to be less than Hb 10 g/dL and Hct 30% and transfusions were performed based on those values for a while [12] . In 1999, a randomized, multicenter, controlled clinical trial that compared a restrictive transfusion trigger (Hb 7 g/dL) and liberal
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Infection
Interest in transfusion-transmitted infections peaked in the 1980s due to transmission of human immunodeficiency virus (HIV) and hepatitis C virus [40] . Subsequent medical advances, along with the use of serological and nucleic acid testing assays, have led to a drastic decline in the number of transfusion-transmitted infections, including HIV and the hepatitis viruses (hepatitis A, B, C) [41, 42] . With respect to infections, today is historically the safest time for a transfusion, but with the emergence of novel viruses, such as the recent Zika virus, transfusion-transmitted cytomegalovirus (CMV) still occurs and it remains a key issue for immunosuppressed patients [43] . Moreover, the posttransfusion infection rate may also increase due to TRIM [44] .
Hemolytic transfusion reaction
A major potential consequence of RBCT is alloimmunization to blood group antigens. Alloimmunization can result in acute hemolytic transfusion reactions [45] , potentially producing significant morbidity and mortality.
One of the most important transfusion-related issues is still administrative error, which is associated with hemolytic transfusion reaction and ABO incompatibilities that lead to mortality in many cases.
Febrile non-hemolytic transfusion reaction
This is a more common reaction than hemolytic transfusion reaction. It is caused by cytokines within the units of red cells. Such cytokines occur when the donor red cells break up during storage or they originate from the donor leukocytes. Such reactions can be reduced by using a leukocyte filter [46] .
Transfusion-related acute lung injury (TRALI)
Currently, TRALI is one of the most dangerous transfusion-associated complication [1] . TRALI is defined as a new acute lung injury occurring within 6 h post transfusion in patients without risk factors for acute lung injury. TRALI typically manifests as shortness of breath, fever, and hypotension [47] . Antibody-medicated TRALI (immune TRALI) is now recognized as one of the most common causes of transfusion-associated major morbidity and death in the Western world [48] . Although TRALI can occur as a result of all types of blood products, it is known to occur more commonly with plasma and pooled buffy coat-derived platelet products, rather than with RBCs (fatal TRALI incidence: plasma, 1:200,000-300,000; platelets, 1:300,000-400,000; RBCs, 1:2,500,000-2,900,000) [49] . The mechanism of TRALI has not been clearly identified, but it can be explained by the 2-hit hypothesis. Antibodies, as well as alternate substances in blood products result in neutrophil activation, which, in a susceptible patient, results in TRALI [49] .
Hypersensitivity transfusion reaction
Hypersensitivity transfusion reaction is a very rare reaction. The biologic mechanism associated with this remains largely unknown, but patients who have had a transfusion-associated adverse reaction may have had an underlying immunodeficiency [50] . Particularly in cases transfused with blood products containing plasma, the development of anaphylaxis, a severe form of hypersensitivity, is highly associated with IgA deficiency, which appears from the production of Ig E Ab against Ig A [51] .
Transfusion-associated circulatory overload (TACO)
Although it is called transfusion-associated circulatory overload (TACO), it is not easy to differentiate between TACO and TRALI. It is a rare complication with less than 100 articles published since its introduction during the 1990s [52] . Therefore, it is difficult to determine whether the exacerbation of pulmonary function occurred as an immunomodulation effect or due to circulatory overload [53] . Other assessments of volume overload, such as jugular venous pressure and B-natriuretic peptide (BNP) levels, can help distinguish the two [46] .
Transfusion-related immunomodulation (TRIM)
Transfusion may trigger an immunologic reaction from the recipient antibody coming together with the donor antigen. This immunologic reaction that has a negative effect on the human immune system is referred to as "transfusion related immunomodulation (TRIM)" [54] .
TRIM is a complex physiological reaction, which is mediated by residual leukocytes, apoptotic cells, and numerous biological response modifiers such as cytokines, soluble mediators, and soluble HLA peptides [55] . TRIM can be explained by two mechanisms, the first of which is HLA-dependent and directed against adaptive immunity, while the second is mild, nonspecific, and directed against innate immunity [56] . Such mechanisms are related to the release of immunosuppressive prostaglandins, suppression of cytotoxic cell and monocyte activity, inhibition of interleukin-2 (IL-2)
production, and an increase in regulatory T cells (Tregs) and suppressor T-cell activity [57] [58] [59] [60] . 
Positive effect of immunomodulation
Immunomodulation may be helpful at times, as indicated by a study result that showed a transfusion improved the survival of the kidney graft in patients who received one [84] . Moreover, among Crohn's disease patients with small bowel resection, the recurrence rate of Crohn's disease was lower in the group that received a transfusion when compared to the group that did not [85] . Therefore, when immunosuppression is required for therapeutic purposes, immunomodulation from a transfusion may be helpful.
Cancer risk

Cancer & immunomodulation
The American Society of Clinical Oncology/American
Society of Hematology introduced transfusion as an effective treatment strategy for improving the health of cancer patients with chemotherapy-associated anemia [86] . However, numerous studies have reported that recurrence and metastasis of cancer increased following transfusion [87] [88] [89] [90] and this is suspected to be the result of immunosuppression following allogenic RBCT [91] . Study results on patients who underwent a Le Fort I osteotomy showed that the average blood loss in a group that used hypotensive anesthesia was 740 ml, whereas the average blood loss in the control group was 400 ml [136] . Furthermore, preoperative and intraoperative administration of the antifibrinolytic agent, tranexamic acid, is effective for controlling blood loss and improving the quality of the surgical field [137] .
Influence on double-jaw surgery
Influence on extra-operation
There are numerous study results indicating that RBCT in non-cancer surgeries result in poor prognosis. RBCT of 3 or more U during liver transplantation surgery increased the length of the hospital stay [138] . The patient group that received RBCT during a coronary artery bypass had a 5-year mortality that was twice as high as that of the group without RBCT [139] . In transcatheter aortic valve implantation surgery cases, using RBCT resulted in an increased 12-month mortality and prolonged hospital stay [140] . Even in major vascular surgery cases, RBCT increased the risk of myocardial infarction and 30-day mortality [141] . RBCT also induced a minor wound-healing disturbance in hip replacement surgery cases, while also increasing the length of the hospital stay [142] . For general surgery, 1 U RBCT increased the risk of 30-day mortality, composite morbidity, pneumonia, and sepsis/shock, while 2 U RBCT increased these outcome risks, as well as surgical-site infections [143] .
AMOUNT OF TRANSFUSION
Are there differences in adverse effects according to the amount of transfused RBCs? A study comprised of 89,000 patients reported that the mortality and morbidity were higher in the patient group that received 1U RBCT than the non-transfused patient group, showing a dose-dependent tendency [144] . Besides mortality, wound problems, pulmonary complications, postop renal dysfunction, sepsis, morbidity, and length of the hospital stay were reported to be high in the group that received RBCT than that in the group that did not and caution was recommended when performing transfusions on patients with a mild anemia [144] . Other studies have reported poor outcomes when 2 U of RBC was used compared to that when 1 U was used [143] . Even in the field of orofacial surgery, there is evidence that a greater amount of RBCT has a greater negative effect on the outcome [127, 130] . In contrast, a study that compared restrictive (Hb < 7 g/dL) vs liberal (Hb < 9 g/dL) strategy on ICU patients who underwent major cancer surgery reported a higher rate of major complications in the restrictive group despite using a lesser amount of RBCT [145] .
Amount of transfusion and bleeding in double-jaw surgery
Orofacial surgery may be associated with significant bleeding. The amount of blood loss and transfusion is always a concern during double jaw surgery. In single jaw surgery, RBCT is considered unnecessary [146] [147] [148] .
However, studies published prior to 2005 show that the average amount of bleeding in double jaw surgery ranged from 344 ml to 889 ml, while the percentage of RBCT varied widely between 0.8 % and 30 % [146, [148] [149] [150] [151] [152] .
Meanwhile, recent studies ( Table 2 shown that a few cases required RBCT, the amount of blood loss in double-jaw surgery was higher than that during other surgeries and some cases required transfusion. Therefore, it is necessary to prepare for situations that require a transfusion while continuously monitoring perioperative bleeding. [158] [159] [160] . Because of this reason, transfusion using "old" RBC may cause adverse effects, including a higher infection risk and higher transfusion-dependent mortality rate [161] [162] [163] .
YOUNG (FRESH) VS OLD RBC
Actually, a large-scale study conducted in Australia, Canada, Israel, and the US showed that the group that received a transfusion of "young" RBCs had a better prognosis than the group that was transfused with "old"
RBCs [164] . However, there are other studies that report no difference in prognoses between the two groups [165] and a study that reports that an "old" RBC transfusion had the benefit of reducing cancer recurrence [163] .
Therefore, this is an issue still under debate and there is the need for a sufficient discussion on issues that can arise a preference for "young" RBCs.
AUTOLOGOUS BLOOD TRANSFUSION
Various aforementioned RBCT risks are mostly associated with allogenic transfusion. An allogenic RBCT is not only the cause of various adverse events, but it also increases the economic and psychological burden of the patient. On the other hand, an autologous transfusion can avoid various adverse events associated with an allogenic transfusion, while addressing the issue of lack of blood and reducing the economic burden of the patient [166, 167] . A randomized study on CRC surgery reported that the recurrence rate was lower with autologous RBCT compared to that of an allogenic RBCT [168] . An autologous RBCT is frequently used during double-jaw surgery in the field of orofacial surgery and an autologous RBCT can serve as a method for reducing allogenic RBCT [169] . The following are the three options for an autologous RBCT: preoperative autologous blood donation (PABD), acute normovolemic hemodilution (ANH), and intraoperative and postoperative autotransfusion.
Preoperative autologous blood donation (PABD)
PABD refers to the method of drawing blood from the patient preoperatively and keeping it until reinjecting it into the patient intra-or postoperatively. Repeated blood donations before surgery can stimulate bone marrow cell proliferation, stimulate erythrocyte regeneration, increase hematopoietic function in patients after surgery, accelerate the patient's hematopoietic recovery after surgery, is conducive for wound healing, and reduces the chances of infection caused by immunoreaction from allogenic RBCT [170] . In addition, the improved autologous RBCT has a number of advantages such as the mild dilution of blood, improved microcirculation, reduction in blood viscosity, and prevention of hypoxia caused by anemia after blood donation [171] .
For Hb ≥ 11 g/dL, donation 4 days prior to surgery is recommended, but donations for a ≥ 8-9 ml/kg is not recommended. Oral iron may be helpful for restoring the Hb to the level prior to donation. Contraindications include bacteremia and acute localized infection, myocardial infarction in the past 6 months, unstable angina, aortic stenosis, congestive heart failure, significant ventricular arrhythmias, marked uncontrolled hypertension, and cerebrovascular accident within 6 months.
Acute normovolemic hemodilution (ANH)
ANH is a method of autologous transfusion, which was first introduced in 1946, and is still widely used today [171] . ANH is generally performed under general anesthesia and prior to the start of surgery. Blood is drawn from the patient and stored and an equivalent amount of crystalloid (1:3) or colloid (1:1) fluid is added to maintain the plasma volume. If required intra-or postoperatively, the collected blood can be reinjected to the patient [172] .
ANH can effectively reduce erythrocyte loss caused by perioperative bleeding and reduce allogenic RBCT [173, 174] . This method is widely used for postpartum hemorrhage and cancer and orthopedic surgeries, such as joint replacement and spine surgery. Moreover, this method is used in the field of dentistry when cancer or double jaw patient with expected bleeding is a Jehovah's Witness [175] . This method offers several advantages.
The first is the reduction of perioperative erythrocyte loss since crystalloid or colloid, in equivalent amount as blood collected, is used to restore volume. This enhances the body's tolerance and reduces actual blood loss [172, 176] .
The second advantage is that it is simpler and less costly than the PABD method. The third advantage is that it is the only method that can provide fresh autologous blood that has almost no effect on the functions of platelets and clotting factors. ANH may be used in cases where Hb is > 11 g/dL and platelets are > 100 x 109 /L and the prothrombin time and cardio-pulmonary function are normal [177] .
Intraoperative or postoperative autotransfusion
Intraoperative or postoperative autotransfusion refers to a method of transfusion in which the blood in the body cavity of a patient, blood lost during surgery, and postoperatively drained blood, can be recovered through a blood recovery device [171] . The blood subsequently undergoes anticoagulation, filtration, and washing and is finally transfused back to the patient [178] . The American 
